933 patents
Page 13 of 47
Utility
Combination of a PD-1 Antagonist, a Vegfr/fgfr/ret Tyrosine Kinase Inhibitor and a Cbp/beta-catenin Inhibitor for Treating Cancer
29 Dec 22
The present disclosure describes a combination therapy comprising an antagonist of Programmed Death 1 receptor (PD-1), a lenvatinib or a pharmaceutically acceptable salt thereof, and (6S,9aS)-N-benzyl-8-({6-[3-(4-ethylpiperazin-1-yl)azetidin-1-yl]pyridin-2-yl}methyl)-6-(2-fluoro-4-hydroxybenzyl)-4,7-dioxo-2-(prop-2-en-1-yl)hexahydro-2H-pyrazino[2,1-c][1,2,4]triazine-1(6H)-carboxamide (E7386) or a pharmaceutically acceptable salt thereof,—and the use of the combination therapies for the treatment of a cancer.
Yoichi OZAWA, Yasuhiro FUNAHASHI, Yu KATO
Filed: 28 Oct 20
Utility
Anti-cancer Combination Therapies Comprising CTLA-4 and PD-1 Blocking Agents
29 Dec 22
Anti-cancer combination therapies comprising a CTLA-4 blocking agent and a PD-1 blocking agent are disclosed.
Drake LaFace, Juha Punnonen, Edward Bowman, David Bauche, Alissa Chackerian, Jeffery Grein, Smita Mauze, Anandi Sawant, Lakshmanan Annamalai
Filed: 10 Mar 20
Utility
A Multiplex Method of Preparing a Sequencing Library
29 Dec 22
A method of preparing a library of library constructs by multiplex amplification for use in targeted next generation sequencing is described.
Nathan Campbell
Filed: 11 Sep 20
Utility
Method and system for external fish parasite monitoring in aquaculture
27 Dec 22
A method for external fish parasite monitoring in aquaculture, comprising the steps of: —submerging a camera (52) in a sea pen containing fish, the camera having a field of view; —capturing images of the fish with the camera (52); and—identifying external fish parasite on the fish by analyzing the captured images, characterized in that a target region within the field of view of the camera (52) is illuminated from above and below with light of different intensities and/or spectral compositions.
Russel Howe, Zachary Lizer, James Wallace Sarrett, Peter Jon Abrahamson, Jascha Tucker Little
Filed: 19 Dec 18
Utility
Device for administering a fluid
27 Dec 22
Frank Altermann, Dominic Kamenzin, Thomas Schmidt, Manuel Mattes, Robin Sauter, Daniel Seeh
Filed: 26 Mar 19
Utility
Small Molecule Inhibitors of Kras G12C Mutant
22 Dec 22
Andrew J. Hoover, Thomas H. Graham, Xiaoshen Ma, Zahid Hussain, Mihir Mandal, Symon Gathiaka, Yongxin Han, David L. Sloman
Filed: 18 Sep 20
Utility
In Vitro Cell Based Potency Assay
22 Dec 22
The present disclosure provides an in vitro cell based potency assay to determine the relative potency of a composition, including a pharmaceutical composition, comprising an mRNA encapsulated in a lipid nanoparticle (LNP) as compared to a reference sample.
Peter A. DePhillips, Nisarg M. Patel, Jingyuan Xu, Zhi-Qiang Zhang
Filed: 30 Nov 20
Utility
Method for producing (5S)-4-[5-(3,5-dichlorophenyl)-5-(trifluoromethyl)-4H-isoxazol-3-yl]-2-methyl-benzoic acid
20 Dec 22
The present invention relates to a novel method for preparing (5S)-4-[5-(3,5-dichlorophenyl)-5-(trifluoromethyl)-4H-isoxazol-3-yl]-2-methyl-benzoic acid, which can preferably be used in the synthesis of (5S)-4-[5-(3,5-dichlorophenyl)-5-(trifluoromethyl)-4H-isoxazol-3-yl]-N-[2-oxo-2-(2,2,2-trifluoroethylamino)ethyl]-2-methyl-benzamide.
Harald Schmitt
Filed: 20 Dec 19
Utility
Cyclic polypeptides for PCSK9 inhibition
20 Dec 22
Provided herein are cyclic polypeptide compounds that can, e.g., bind specifically to human proprotein convertase subtilisin/kexin type 9 (PCSK9) and optionally also inhibit interaction between human PCSK9 and human low density lipoprotein receptor (LDLR), and pharmaceutical compositions comprising one or more of these compounds.
Alonso Ricardo, Thomas Joseph Tucker, Nicolas Cedric Boyer, Joseph R. Stringer, Derek M. LaPlaca, Angela Dawn Kerekes, Chengwei Wu, Sookhee Nicole Ha, Hyewon Youm, Mark W. Embrey, Elisabetta Bianchi, Danila Branca, Raffaele Ingenito, Willy Costantini, Alessia Santoprete, Roberto Costante, Immacolata Conte, Stefania Colarusso, Eric J. Gilbert, Aurash Shahripour, Yusheng Xiong
Filed: 20 Jun 19
Utility
Tyrosine-specific functionalized insulin and insulin analogs
20 Dec 22
The present invention relates to tyrosine-specific functionalized insulin analogs and processes of making such tyrosine-specific functionalized insulin analogs using R-3H-1,2,4-triazoline-3,5-(4H)diones (PTAD).
Ahmet Kekec, Nancy Jo Kevin, Bing Li, Songnian Lin, Craig A. Parish, Weijuan Tang
Filed: 18 Mar 19
Utility
Spiropiperidine Allosteric Modulators of Nicotinic Acetylcholine Receptors
15 Dec 22
Ian M. Bell, Brendan M. Crowley, Phillippe Nantermet
Filed: 29 Oct 20
Utility
Novel Substituted 1,3-8-TRIAZASPIRO[4,5] DECANE-2,4-DIONE Compounds As Indoleamine 2,3-DIOXYGENASE (Ido) And/or Tryptophan 2,3-DIOXYGENASE (Tdo) Inhibitors
15 Dec 22
Yongxin Han, Yongqi Deng, David Jonathan Bennett, Philip M. Cowley, Alan Wise
Filed: 14 Dec 20
Utility
Method for Measuring Nucleic Acid Content In Lipid Nanoparticles Using Ultraviolet Spectrometry
15 Dec 22
An ultraviolet (UV) absorbance assay for measuring the concentration of large RNA molecules such as mRNA in suspensions comprising RNA-lipid nanoparticles (RNA-LNPs) is described.
Lee J. Klein, Leia C. Epstein
Filed: 22 Sep 20
Utility
Pneumococcal polysaccharides and their use in immunogenic polysaccharide-carrier protein conjugates
13 Dec 22
The present invention provides capsular polysaccharides from Streptococcus pneumoniae serotypes identified using NMR.
Richard J. Porambo, Chitrananda Abeygunawardana, Luwy Kavuka Musey, Michael J. Kosinski, Yadong Adam Cui, Patrick McHugh, Janelle Konietzko
Filed: 4 Sep 18
Utility
Labeling Shell for a Drug Vial
8 Dec 22
In one aspect of the subject invention, a labeling shell is provided for a drug vial having a glass reservoir and an opening sealed by an elastomeric stopper, the labeling shell including: a polymeric tubular body formed to accommodate the reservoir of the drug vial, the tubular body having a first open end defining a first opening smaller than a diameter of the reservoir of the drug vial so as to prevent passage therethrough of the reservoir, wherein the elastomeric stopper is exposed through the first end with the reservoir being accommodated in the tubular body; and, a polymeric cap removably mountable to the tubular body to selectively cover the elastomeric stopper of the drug vial with the reservoir being accommodated in the tubular body.
Eduardo Cristofolli, John B. Cline, Wail Rasheed, Raymond K. Seto, Steven Carl Persak, Tinh Nguyen-Demary
Filed: 10 Nov 20
Utility
a Novel Vaccine Against Heamophilus Parasuis
8 Dec 22
The invention pertains to a serine protease antigen which induces antibodies against a protein having at least 69% sequence identity with the Heamophilus parasuis protein according to SEQ ID No: 1, for use in a prophylactic method to protect a pig against an infection with Haemophilus parasuis by administering a vaccine to the pig, wherein the vaccine comprises the serine protease antigen.
Antonius Arnoldus Christiaan Jacobs, Theodora Johanna Van Kasteren-Westerneng, Johanna Jacoba Elisabeth Bijlsma
Filed: 19 Nov 20
Utility
Novel Synthetic Pathway to Belzutifan and Crystalline Phases of Synthetic Intermediates
8 Dec 22
Stephen M. Dalby, Clinton Scott Shultz, Chintal Desai, Joshua Lee, Zhiwei Chen, Jungchul Kim, Nastaran Salehi Marzijarani, Tao Wang, Eric M. Phillips, Patrick Larpent, Het P. Patel, Haiheng Guo, Xin Wang, Kangze Dai, Lu Chen, Teng Li, Taotao Lu, Jianjun Duan
Filed: 20 May 22
Utility
PD-L1 Antibodies Binding Canine PD-L1
8 Dec 22
The present invention discloses antibodies including caninized antibodies against canine PD-L1 with specific properties.
Mohamad Morsey, Yuanzheng Zhang, Denise Bartels-Morozov, Jason Erskine, Ian Tarpey
Filed: 15 Aug 22
Utility
Recombinant Expression of Chlamydia Momp Antigen
1 Dec 22
The present invention relates to methods for the recombinant expression of chlamydia major outer membrane protein (MOMP) comprising transforming a population of E. coli host cells with an expression vector comprising a nucleic acid molecule that encodes chlamydia MOMP and encodes a leader sequence for targeting the MOMP to the outer membrane of the cell, wherein the nucleic acid molecule is operatively linked to a promoter.
Lan Zhang, Zhiyun Wen, Craig T. Przysiecki, Puneet Khandelwal, Ping Qiu
Filed: 1 Jul 22
Utility
a Novel Vaccine Against Heamophilus Parasuis
1 Dec 22
The invention pertains to a protein having at least 69% sequence identity with the protein according to SEQ ID No: 1 or an immunogenic fragment of this protein, for use in a prophylactic method to protect a pig against an infection with Haemophilus parasuis serotype 4 and an infection with Haemophilus parasuis serotype 5, by administering a vaccine to the pig, the vaccine comprising the protein or the immunogenic fragment thereof as an antigen.
Antonius Arnoldus Christiaan Jacobs, Theodora Johanna Van Kasteren-Westerneng, Johanna Jacoba Elisabeth Bijlsma
Filed: 19 Nov 20